All In Biotech

Drug Trial Radar · NCT04409509

Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19)

A Phase 2, Multicenter, Double Blind, Randomized, Placebo-Controlled Study to Evaluate CSL312 in Coronavirus Disease 2019 (COVID 19)

Last checked: Nov 20, 2026Latest source record: Jan 24, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 124 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

124

Actual

Start

Jul 1, 2020

Primary completion

Jan 12, 2021

Study completion Jan 12, 2021

Sponsor

Lead sponsor
CSL BehringIndustry
Sponsor type
Industry
First posted
Jun 1, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, phase 2, multicenter, randomized, double blind, placebo controlled, parallel group study to assess the safety and efficacy of CSL312 administered intravenously, in combination with standard of care (SOC) treatment, in patients with Coronavirus disease 2019 (COVID 19)

Conditions

  • Coronavirus Disease 2019 (COVID-19)

Interventions

  • Garadacimab, Factor XIIa Antagonist Monoclonal AntibodyBiological

    Garadacimab, Factor XIIa Antagonist Monoclonal Antibody administered intravenously

  • PlaceboDrug

    CSL312 diluent administered intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Percent of Participants With Tracheal Intubation or Death Prior to Tracheal IntubationTime frame: From randomization to Day 28

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Nova Clinical Research, LLC

    Bradenton, Florida

  • Theia Clinical Research, LLC

    St. Petersburg, Florida

  • MercyOne North Iowa Medical Center

    Mason City, Iowa

  • Northeast Iowa Medical Education Foundation

    Waterloo, Iowa

  • Lahey Hospital and Medical Center

    Burlington, Massachusetts

  • University of Mississippi Medical Center

    Jackson, Mississippi

  • Holy Name Hospital

    Teaneck, New Jersey

  • Inspira Health Center Vineland

    Vineland, New Jersey

  • Sisters of Charity Hospital/ St. Joseph's Campus

    Buffalo, New York

  • Carolina Institute for Clinical Research

    Fayetteville, North Carolina

  • Monument Health Clinical Research

    Rapid City, South Dakota

  • PharmaTex Research

    Amarillo, Texas

  • UT Health Science Center, McGovern Medical School

    Houston, Texas

  • Inova Alexandria Hospital

    Alexandria, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.